The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASH 2015 | Highlights of ASH in CLL

Name: Highlights of ASH in CLL
Uploaded: 2015-12-04T00:00:00.000Z
Duration: 1 min 35 s
Description: At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the recent developments occuring in CLL and how certain molecules such as Bcl-2, BTK and PI3K, have moved from being biomarkers and stratification markers to becoming targets of the disease.

John Gribben and Stephan Stilgenbauer • 4 Dec 2015

ASH 2015

Chronic Lymphocytic Leukemia

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the recent developments occuring in CLL and how certain molecules such as Bcl-2, BTK and PI3K, have moved from being biomarkers and stratification markers to becoming targets of the disease.